Tracers / [161Tb]Tb-DOTATATE
[161Tb]Tb-DOTATATE
Also written as DOTATATE; [Tb-161]Tb-DOTATATE; DOTA-TATE; dotatate
- Radionuclide
- Tb-161 t½ 9907.2 min
- Modality
- Therapy
- Production route
- —
- Stage
- —
- Syntheses indexed
- 4
What it is
- Compound class
- DOTATATE somatostatin analogue (radiolabelled peptide)
- Target / mechanism
- Somatostatin receptor 2 (SSTR2) agonist PMID 42518020
- Clinical application
- —
- Theranostic pair
- <a href="/tracers/ga68-dotatate/">ga68-dotatate</a>
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | — | >97% | >90% | DOTATATE Bachem, Bubendorf, Switzerland | 42518020 2026 EJNMMI Res Radiolabelling was performed by mixing DOTATATE (1.5 ug; 1 mg/mL in metal free water) (Bachem, Bubendorf, Switzerland) with approximately 60 MBq of non-carrier added [161Tb]TbCl3 — The reaction consistently produced a high radiochemical yield, averaging > 97%. |
| Manual synthesis | — | none | — | >98% | DOTATATE Bachem, Bubendorf, Switzerland | 39046521 2024 Eur J Nucl Med Mol Imaging DOTA-LM3 (CSBio, Silicon Valley Menlo Park, California, United States) and DOTATATE (Bachem, Bubendorf, Switzerland) were labeled with terbium-161 or lutetium-177 at a molar activity of up to 100 MBq/nmol using standard labeling conditions as previously reported |
| — | — | — | >99% | >99% | DOTATATE | 42411199 2026 Nucl Med Commun [161Tb]Tb-DOTATATE was prepared by reconstituting DOTATATE in sodium acetate buffer (pH 4.5), along with ascorbic acid as a radio-stabilizer. — the radiolabeling yield, which was greater than 99% at 1 h |
| — | — | — | — | — | — | 42167802 2026 J Nucl Med |
Need this precursor?We can point you to suppliers for [161Tb]Tb-DOTATATE, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 5 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Diagnostic pair signal at discovery: YES - Cu-64, Ga-68. Compound class inferred from precursor name (not stated outright) -- PMID 42518020: 'DOTATATE (1.5 ug; 1 mg/mL in metal free water) (Bachem, Bubendorf, Switzerland)'. | Stage 28: added indication(s) onc-neuroblastoma from consolidated missing-rubric review.